Gilead Sciences (GILD) Revenue — Quarter Ended Sep 30, 2025
Gilead's revenue for the quarter increased compared to the immediately preceding quarter and also rose relative to the same quarter one year earlier. The sequential growth was particularly notable, contributing to a solid trailing twelve-month revenue result.
Key takeaway
Quarter ended Sep 30, 2025 · FY2025 Q3
Gilead's revenue for the quarter increased compared to the immediately preceding quarter and also rose relative to the same quarter one year earlier. The sequential growth was particularly notable, contributing to a solid trailing twelve-month revenue result.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$7.8B
Revenue reported for this quarter.
Quarter-over-quarter
+9.7%
Change from the immediately preceding quarter.
Year-over-year
+3.0%
Change from the comparable year-ago quarter.
Trailing four quarters
$29.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2024 | $7.6B | +6.4% |
| Mar 31, 2025 | $6.7B | -0.3% |
| Jun 30, 2025 | $7.1B | +1.8% |
| Sep 30, 2025 | $7.8B | +3.0% |
Revenue performance
The reported revenue reflects a strong quarterly performance, with growth accelerating from the prior period.
Quarterly comparison
Sequentially, revenue increased markedly from the previous quarter. On an annual basis, revenue also registered a gain compared to the same period last year.
What to watch
Cash flow from operations for the first nine months of the fiscal year declined compared to the same period last year, which may warrant attention.